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Duchenne muscular dystrophy (DMD) is characterized by muscle degeneration and
progressive weakness. There is considerable inter-patient variability in disease onset and
progression, which can confound the results of clinical trials. Here we show that a common
null polymorphism (R577X) in ACTN3 results in signiﬁcantly reduced muscle strength and a
longer 10m walk test time in young, ambulant patients with DMD; both of which are primary
outcome measures in clinical trials. We have developed a double knockout mouse model,
which also shows reduced muscle strength, but is protected from stretch-induced eccentric
damage with age. This suggests that a-actinin-3 deﬁciency reduces muscle performance at
baseline, but ameliorates the progression of dystrophic pathology. Mechanistically, we show
that a-actinin-3 deﬁciency triggers an increase in oxidative muscle metabolism through
activation of calcineurin, which likely confers the protective effect. Our studies suggest that
ACTN3 R577X genotype is a modiﬁer of clinical phenotype in DMD patients.
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D
uchenne muscular dystrophy (DMD) is an X-linked
genetic disorder characterized by progressive muscle
degeneration and weakness. DMD is caused by mutations
in the DMD gene, resulting in loss of dystrophin protein at the
muscle membrane1. To date, the only proven palliative therapy
for DMD is chronic corticosteroid (that is, prednisone or
deﬂazacort) treatment2,3, the effects of which can be highly
variable between patients. There is also considerable inter-patient
variability in disease onset and progression4. This presents a
signiﬁcant challenge to clinicians in counselling patients and
threatens to mask the beneﬁts of novel treatments, and confound
the results of clinical trials.
It has long been hypothesized that genetic variations at loci
independent of dystrophin (that is, genetic modiﬁers) are
responsible for unexplained variability in the progression of
muscle weakness and response to therapies in patients with
DMD. The ﬁrst disease modifying gene to be identiﬁed in DMD
patients, osteopontin (SPP1), was reported in 2011. A single
nucleotide polymorphism (SNP) in SPP1, resulting in reduced
gene expression, was associated with greater muscle weakness and
earlier loss of ambulation (LoA)5. The mechanism underlying this
effect on DMD phenotype has not yet been determined, but SPP1
expression is known to affect muscle regeneration6 and is
upregulated in DMD patients7. Importantly, when stratifying
cohorts based on SPP1 genotype, the number of patients required
to detect a signiﬁcant difference in a clinical trial setting is
reduced by roughly 75%. More recently, LTBP4 was found to
inﬂuence the age at which patients with DMD became
non-ambulant via modulation of the TGF-b signalling
pathway8,9. The modiﬁer effect on LoA has since been
replicated for both of these genes in a large patient cohort, but
only when the cohort was stratiﬁed for both ethnicity and
corticosteroid treatment, highlighting the difﬁculty associated
with identifying genetic modiﬁers.
Interestingly, both SPP1 and LTBP4 map to the TGF-b
pathway, a key driver of failed regeneration and the development
of ﬁbrosis in DMD (ref. 10), highlighting the potential for genetic
modiﬁers to reveal molecular pathways which drive the
dystrophic pathology. The ongoing identiﬁcation of modiﬁer
genes is therefore of considerable importance as they contribute
to our understanding of the pathological mechanisms that
underpin DMD, and will have a major inﬂuence on future
clinical trial design.
In skeletal muscle, the sarcomeric a-actinins are the major
components of the Z-line where they bind and crosslink the actin
thin ﬁlaments. a-Actinin-2 is expressed in all muscle ﬁbres, but
the highly homologous a-actinin-3 isoform is expressed only in
fast, glycolytic ﬁbre types. Importantly, there is a common
null polymorphism (R577X, rs1815739) in the gene coding for
a-actinin-3 (ACTN3), resulting in complete absence of a-actinin-
3 in homozygous individuals (ACTN3 577XX, B16% of the
global population and B18% of Caucasians)11. a-Actinin-3
deﬁciency is detrimental to sprint and power performance in both
elite athletes12,13 and the general population14–16. Conversely,
a-actinin-3 deﬁciency is associated with increased endurance
performance in some athlete cohorts13,17, and improved response
to resistance training14. Actn3 knockout (KO) mice mimic
the phenotype seen in a-actinin-3 deﬁcient humans; Actn3 KO
mice have reduced muscle mass and strength18, but display
increased endurance capacity, fatigue resistance and response to
training19,20.
Actn3 KO mice do not exhibit a change in ﬁbre type
distribution at baseline, but the fast 2B ﬁbres, which would
usually express a-actinin-3, display a shift towards the properties
classically associated with slower ﬁbre types including; reduced
ﬁbre diameter18, increased oxidative metabolism18,21,22, slowed
relaxation from contraction23 and an increased recovery from
fatigue19. The mechanism responsible for this shift in fast-to-slow
properties is likely because of a combination of metabolic and
signalling changes in the absence of a-actinin-3. Speciﬁcally, we
have identiﬁed increases in glycogen storage (because of a
reduction in glycogen phosphorylase activity)22 along with
increased calcineurin activity in Actn3 KO muscle20, which
together promote greater oxidative metabolism and a fast-to-slow
ﬁbre type conversion in skeletal muscle.
It is clear that ACTN3 genotype signiﬁcantly inﬂuences muscle
function in both elite athletes and healthy individuals and hence
may also be capable of modifying muscle function in DMD
patients. Slower, more oxidative ﬁbres are relatively spared from
degeneration in DMD (ref. 24). In addition, calcineurin over-
expression in mdx mice has been demonstrated to ameliorate the
dystrophic phenotype25,26. Taken together these data led us to
hypothesize that ACTN3 is capable of acting as a genetic modiﬁer
of DMD, and that the shift towards slower muscle metabolic
properties associated with a-actinin-3 deﬁciency may have a
protective effect against the pathogenesis of DMD. Here we show
that the common null polymorphism (R577X) in ACTN3 results
in signiﬁcantly reduced muscle strength and a longer 10m walk
test time in young, ambulant patients with DMD. Using an Actn3
KO mdx (double KO) mouse model, we show a similar reduction
in muscle strength, but protection from stretch-induced eccentric
damage with age. Mechanistically, a-actinin-3 deﬁciency triggers
an increase in oxidative muscle metabolism through activation
of calcineurin, which likely confers the protective effect. This
work therefore suggests that a-actinin-3 deﬁciency reduces
muscle strength performance, but ameliorates the progression
of dystrophic pathology.
Results
ACTN3 genotype modiﬁes strength in ambulant DMD patients.
To assess muscle function in DMD, we analysed baseline data on
a cohort of DMD patients (n¼ 272) enroled in the Cooperative
International Neuromuscular Research Group (CINRG) DMD
natural history study (DNHS). We stratiﬁed this cohort to include
steroid treated, ambulant, (young) 6–10 year old (n¼ 61) and
analysed quantitative muscle testing (QMT) and timed functional
testing (10m walk velocity); this approach is considered to pro-
vide the most sensitive and reliable phenotype to assess genetic
modiﬁers27.
At baseline, ACTN3 genotype had a signiﬁcant effect on both
isolated muscle strength (grip QMT, knee and elbow extensor
QMTs) and overall muscle function (10m walk test). In all cases,
the ACTN3 577X allele was associated with poorer muscle
performance; ACTN3 577RX patients display signiﬁcantly less
strength across the QMTs and took signiﬁcantly longer to
complete the 10m walk test compared with patients with ACTN3
577RR genotype. Similarly, patients with the ACTN3 577XX
genotype show a trend for reduced muscle power output across
all outcome measures in the cohort (Table 1).
Young dKO mice display reduced strength. To explore the
ACTN3 genotype effect observed in DMD patients, we crossed
Actn3 KO mice18 with the mdx mouse model of DMD, to create a
double knockout model (dKO) lacking both a-actinin-3 and
dystrophin. In agreement with our observations in ambulant
DMD patients, muscles from young dKO mice (aged 8 weeks)
display signiﬁcantly reduced force producing capacity compared
with mdx controls (Fig. 1a), which is maintained when correcting
for the reduced size of the dKO muscles (Fig. 1b). Interestingly,
both mdx and dKO muscles showed increased recovery from
fatigue compared with WT (Fig. 1c), but we saw no difference
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between mdx and dKO. We saw no difference in the hill
coefﬁcient or twitch time to peak between mdx and dKO, but did
see an increased half-relax time in dKO compared with mdx,
indicating slowed relaxation following contraction (Table 2;
Supplementary Fig. 1A–C). Dystrophic muscle is known to be
vulnerable to stretch-induced damage28, and both mdx and dKO
muscles are injured following a series of 20% eccentric stretches
(Fig. 1d). We examined this phenotype further by inducing
eccentric contractions in vivo via a downhill running protocol,
using Evans blue dye (EBD) to mark injured ﬁbres29. We saw a
signiﬁcantly increased number of EBD-positive ﬁbres in dKO
muscles (Fig. 1e), although this may be a product of the increased
endurance capacity associated with a-actinin-3 deﬁciency20.
A representative image of skeletal muscle following downhill
run shown in Fig. 1f.
a-Actinin-3 deﬁciency ameliorates mdx disease progression. To
determine the inﬂuence of a-actinin-3 deﬁciency on the pro-
gression of the dystrophic pathology, we analysed muscle from
aged (12 month) mice. Similar to our ﬁndings at baseline (8 week
old mice), ex vivo EDL muscles of dKO mice produced less force
than mdx (Fig. 2a), even when corrected for cross sectional area
(Fig. 2b). The half-twitch relaxation time was also increased in dKO
(Table 3). Importantly, aged dKO muscles demonstrated a
signiﬁcant reduction in force deﬁcit following eccentric contraction
compared with mdx controls (Fig. 2c). Aged dKO muscles also
show considerably greater recovery from fatigue than mdx
(Fig. 2d). Given that there was no difference in either parameter at
8 weeks, these ﬁndings suggest that a-actinin-3 deﬁciency protects
against susceptibility to muscle damage with age. We sought to
replicate these ﬁndings in the TA, using an in situ protocol, which
arguably mimics muscle physiology better than the ex vivo EDL
technique, and again saw reduced absolute force (Fig. 2e), max-
imum speciﬁc force (Fig. 2f), and decreased susceptibility to
eccentric damage (Fig. 2g) in dKO compared with mdx.
To understand the phenotypes described above, we studied the
TA histopathology of mdx and dKO mice (Fig. 3a). We observed
a signiﬁcant reduction in necrosis (mdx¼ 10.7%, dKO¼ 4.7%,
Fig. 3b) and an increase (B11%) in centrally nucleated ﬁbres in
dKO muscle compared with mdx (mdx¼ 71.8%, dKO¼ 79.2%,
Fig. 3c). We also examined isolated intact single ﬁbres from the
EDL of WT, mdx and dKO mice for altered branching proﬁles
(Fig. 3d). Fibre branches are known to accumulate over time as a
marker of muscle damage in mdx mice30. Fibres isolated from
dKO showed a small reduction in the number branched
compared with mdx (Fig. 3e), but we observed a drastic
reduction in the complexity of branching in dKO as only 18%
of ﬁbres contained four or more branches, compared with 74% of
mdx (Fig. 3f).
ACTN3 genotype modiﬁes disease progression in DMD patients.
Given that a-actinin-3 deﬁciency ameliorates disease progres-
sion in mdx mice, we tested the effect of ACTN3 deﬁciency
against the progression of DMD in the CINRG DNHS cohort by
analysing LoA and repeated measures of grip QMT over time.
Genotype-speciﬁc Kaplan-Meier plots for LoA in 266 CINRG
Duchenne Natural History Study participants show that
heterozygote (RX) participants suffered 1-year to 2-year earlier
LoA (Fig. 4a): median age at LoA in these participants was 11.7
years (95% CI 11.0–13.0), but no difference was observed
between RR (12.5 years, 95% CI 11.1–14.0) and XX (13.0 years,
95% CI 11.9–14.0). The same pattern was detected when
restricting the analysis to European ancestry: median age at LoA
in the RX genotype was 12.0 years (95% CI 11.0–14.0), versus
13.0 (95% CI 11.1–18.0) in RR and 14.0 (95% CI 12.0–14.5) in
XX. Taking the RR genotype as reference and performing a Cox
regression, including glucocorticoid (GC) treatment as a
covariate, the RX genotype was signiﬁcantly associated with risk
of earlier LoA, with an odds ratio (OR) of 1.44 (95% CI
1.01–2.07, P¼ 0.044). In the smaller European ancestry
sub-cohort, there was a trend in the same direction using the
same statistical test: OR for the RX genotype was 1.64 (95% CI
0.93–2.90, P¼ 0.089). We genotyped the Padova DMD cohort
for rs1815739 (n¼ 102 successfully genotyped), and again
Table 1 | Baseline CINRG natural history cohort analysis.
Phenotype Overall P value N: mean±s.d. Post-hoc P values indicating
signiﬁcantly different means
10 Metre Walk Test (velocity m per sec) 0.0366 RR (N¼ 16; 2.22±0.77)* P¼0.034*
RX (N¼ 29; 1.69±0.65)*
XX (N¼ 16; 1.79±0.54)
Grip QMTw 0.0228 RR (N¼ 16; 4.02±0.66)* P¼0.019*
RX (N¼ 29; 3.43±0.60)*
XX (N¼ 16; 3.67±0.79)
Elbow extensor QMTw 0.0381 RR (N¼ 16; 2.84±0.63)* P¼0.032*
RX (N¼ 27; 2.36±0.55)*
XX (N¼ 16; 2.54±0.57)
Elbow ﬂexor QMTw 0.0641 RR (N¼ 16; 3.10±0.56) NONE
RX (N¼ 27; 2.68±0.60)
XX (N¼ 16; 2.77±0.52)
Knee extensor QMTw 0.0222 RR (N¼ 16; 4.09±1.15)* P¼0.033*
RX (N¼ 27; 3.26±0.95)*
XX (N¼ 16; 3.24±0.93)
Knee ﬂexor QMTw 0.0384 RR (N¼ 16; 3.72±0.43)* P¼0.0384*
RX (N¼ 27; 3.32±0.51)*
XX (N¼ 16; 3.54±0.54)
One-way ANOVA, Sˇida´k adjustment for multiple comparisons.
*denotes genotype groups compared to give the P value shown in column 4.
wSquare root transformed variable.
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observed an earlier median LoA in RX (10.4 years, 95% CI 9.92–
11.6) than RR (11.0 years, 95% CI 10.32–12.7, Supplementary
Fig. 2), but this difference was not signiﬁcant in a Cox regres-
sion model including GC treatment. Median age at LoA in the
XX group was 10.2 years, 95% CI 9.8 – undetermined upper
limit because of a low number of individuals with this genotype
(n¼ 10). To test concurrent effects of ACTN3 genotype,
previously known genetic modiﬁer genotypes (SPP1 rs28357094
and LTBP4 rs10880), and GC treatment, we devised a Cox
regression model including 297 participants of self-identiﬁed
European ancestry, from both the CINRG DNHS and Padova
Cohort, for whom all these data were available. In this model,
the effect of the ACTN3 RX genotype was detrimental (OR 1.45,
95% CI 1.05–2.00, P¼ 0.022), while the homozygous XX gen-
otype was not (Supplementary Table 1). The strong effect of
GCs in delaying LoA was conﬁrmed by this analysis, which
showed a 3.1 year delay of LoA with treatment (OR 0.23, 95% CI
0.16–0.31, Po0.0001, see Supplementary Table 1), stressing the
importance of including GC treatment in the statistical model
for genotype effects.
We also examined grip QMT over a 4 year period in steroid
treated 6–10 year olds using mixed effects linear regression
(Fig. 4b). Similar to our ﬁndings at baseline, we see a reduction in
strength associated with the X allele as RX individuals
show a mean grip strength which is 0.471 lbs less than RR
(95% CI 0.172–0.770, P¼ 0.002) and 0.283 lbs less for XX
individuals (95% CI 0.062–0.628, P¼ 0.108). When we combined
all genotypes, we did not see a difference in grip strength over
time, suggesting that the dystrophic pathology counteracts the
natural increase in strength one would expect during childhood
development between these two ages. However, we did see a
signiﬁcant interaction between ACTN3 genotype and time
(P¼ 0.021). This suggests that ACTN3 genotype signiﬁcantly
inﬂuences grip strength over time, although the magnitude of this
inﬂuences was not evaluated at the individual genotype level, but
instead as a single genotype factor.
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Figure 1 | Baseline muscle physiology from 8 week old mice. (a) dKO muscles produceB33% less force than mdx controls (mdx - 204.9 mN, dKO - 138.3
mN, Po0.001). (b) When corrected for cross-sectional area, dKO muscles produce signiﬁcantly less maximum speciﬁc force than mdx. (c) Both mdx and
dKO show signiﬁcantly greater recovery from fatigue than WT, but no difference was observed between mdx and dKO. (d) dKO muscles suffer slightly less
damage than mdx controls following a series of 6 20% eccentric contractions (mdx 45% drop in force following eccentric contractions, dKO 38%,
P¼0.08). A subset of the WT EDL muscle physiology data was previously published in Hogarth et al.43 (e) A higher percentage of gastrocnemius muscle
ﬁbres are EBD-positive following a downhill run in dKO mice than mdx. (f) Representative cross-section from a dKO gastrocnemius following downhill run.
EBD positive ﬁbres are shown in red and wheat germ agglutinin (Green) was used to delineate the ﬁbre border. Scale bar indicates 500mm. Data shown as
mean±s.e.m., One-way ANOVA, *Po0.05, **Po0.01, ***Po0.001. WT n¼ 11, mdx n¼ 16, dKO n¼ 11.
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Increased calcineurin activity ameliorates pathology in dKO.
Slow ﬁbres are largely spared in the pathogenesis of DMD
(ref. 24), and forced fast-to-slow ﬁbre type conversion via the
overexpression of calcineurin ameliorates the dystrophic
phenotype in mdx mice25,26. The exact mechanism by which
slow ﬁbres are resistant to dystrophy is unclear, but may be the
result of one or more of the following properties - smaller ﬁbre
diameter, increased utrophin expression or a preference for
oxidative metabolism. We sought to test each of these possible
explanations for the protective effect of a-actinin-3 deﬁciency on
disease progression in mdx mice.
We cut sections from the mid-belly of the quadriceps and
co-labelled with antibodies against the different myosin heavy
chain (MyHC) isoforms to investigate ﬁbre size and type
distribution (Fig. 5a). At 12 months, both mdx and dKO showed
a higher frequency of small ﬁbres compared with WT (Fig. 5b).
While this can be attributed in part to the presence of small
regenerating ﬁbres in dystrophic muscle, ﬁbre branches are also
likely included in this analysis as these are difﬁcult to identify in
cross-section and hence are included in the counts. We observed
a signiﬁcant reduction in overall ﬁbre size in dKO muscle
compared with WT (Fig. 5b), which is likely a product of reduced
2B ﬁbre size in these animals (Fig. 5c). However, we did not
observe a shift in ﬁbre type as the relative proportions in MyHC
isoform were unchanged (Fig. 5d).
At a protein level, there is a signiﬁcant increase in the level of
a-actinin-2 in dKO (Fig. 6a,b); this is a characteristic of a-actinin-
3 deﬁcient muscle in Actn3 KO mice, and likely represents a
compensatory upregulation of this closely related protein21,31. In
addition, we have previously observed a signiﬁcant increase in
calcineurin activity in both a-actinin-3 deﬁcient human and
mouse muscle, and demonstrated that this is a likely mechanism
for the slower twitch relaxation time, increased recovery from
fatigue, enhanced response to endurance training and shift
towards an oxidative metabolic phenotype in Actn3 KO mice20.
Calcineurin is a calcium sensitive phosphatase known to signal
fast-to-slow ﬁbre type transition in skeletal muscle32. Here we
show a marked (2-fold) upregulation in the expression of
regulator of calcineurin 1.4 (RCAN 1.4) (which is indicative of
increased calcineurin signalling) in dKO mice compared with
control mdx (Fig. 6a,b); however this was not associated with an
increase in the expression of utrophin or a shift in ﬁbre type
(based on MyHC isoform) at baseline (Supplementary Fig. 3).
AMP-activated protein kinase (AMPK) is another key
regulator of muscle metabolism and also plays a role in the
conversion of fast muscle ﬁbres to a slow ﬁbre phenotype33.
Pharmacological stimulation of AMPK in mdx mice causes
a shift towards oxidative metabolism and ameliorates the
dystrophic pathology34,35. On this basis, we examined the total
and phosphorylated expression levels of AMPK and the
co-regulated protein acetyl-CoA carboxylase (ACC) in mdx and
dKO muscle and observed trend for increased AMPK and ACC
phosphorylation expression at baseline (Fig. 6c,d), providing
further novel evidence for a shift towards a more oxidative muscle
metabolism in a-actinin-3 deﬁcient mdx muscle.
Table 2 | Physiological properties of isolated EDLs from
young WT, mdx and dKO mice.
Parameter WT mdx dKO
EC50 (Hz) 59.4±0.8 55.9±0.3 55.5±1.4
Hill co-efﬁcient 4.2±0.1 4.5±0.1 4.2±0.4
Twitch time to peak (ms) 21.3±2.4 19.3±1.0* 20.2±2.7
Twitch half-relax time (ms) 18.0±472 13.8±2.2* 17.5±4.3w
One-way ANOVA.
*Po0.01 versus WT.
wPo0.01 versus mdx.
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Figure 2 | Muscle physiology from 12 month old mice. (a–d) Ex vivo EDL muscle function. (a) dKO muscles produceB27% less force than mdx controls
(mdx – 171.0 mN, dKO – 126.2mN, One-way ANOVA, Po0.001). (b) When corrected for cross-sectional area, dKO muscles produce signiﬁcantly less
maximum speciﬁc force than mdx. (c) dKO muscles suffer less damage than mdx controls following a series of three 15% eccentric contractions (mdx - 71%
drop in force following eccentric contractions, dKO - 47%, One-way ANOVA, Po0.01). (d) dKO show signiﬁcantly greater recovery from fatigue compared
with WT, and mdx. (e,f) In situ TA muscle function replicates the phenotype seen in the EDL. (e) dKO muscles produceB25% less force than mdx controls
(mdx - 1613 mN, dKO-1221 mN, One-way ANOVA, Po0.01), (f) After correction for cross-sectional area, dKO show reduced speciﬁc force compared with
mdx. Both are signiﬁcantly reduced compared with WT. (g) Both mdx and dKO muscles are signiﬁcantly injured compared with WT by eccentric
contractions of increasing strain (Multiple T-test, FDR 1% #P o0.01), but dKO muscles suffer less damage than mdx between 25-30% LO (0–35%;
mdx – 80% drop in force following eccentric contractions, dKO 65%, Multiple T-test, FDR 1%, Po0.05). Data shown as mean±s.e.m., One-way ANOVA,
*Po0.05, **Po0.01, ***Po0.001, WT n¼ 5, mdx n¼6, dKO n¼6.
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Given the increase in two of the key regulators of oxidative
metabolism (calcineurin and AMPK) we assessed the dKO mouse
at baseline for changes in Pgc-1a mRNA expression and markers
of oxidative phosphorylation. In dKO muscle we observed a
B2-fold increase in Pgc1-a mRNA when normalizing mRNA
expression to the geometric mean of four reference genes
(One-way ANOVA, P¼o0.01), with no obvious change in
protein expression (Supplementary Fig. 4). We also see evidence
for a shift in mitochondrial function as dKO muscle shows
upregulation in the expression of ATP synthase (B16%, ATPase),
succinate-Q oxidoreductase (B30%, Complex II), cytochrome-c
oxidoreductase (B18%, Complex III) and cytochrome c oxidase
(B44%, Complex IV) compared with mdx controls (Fig. 6e,f).
Discussion
Recent advances in muscular dystrophy research have resulted in
an increased number of potential therapies and subsequent
clinical trials to treat DMD and slow disease progression36,37.
While this is exciting, the detection of unequivocal therapeutic
beneﬁt in these trials has been challenging and they are not
currently approved for use by patients. One reason for this lack of
translation into clinical practice is because of the absence of clear
positive outcomes from current clinical trial data38. Though this
may be because of failed utility of the drug or treatment, the large
inter-patient variability in response to many of these agents has
made it difﬁcult to draw conclusions (positive or negative) from
many of these studies. It is increasingly recognized that the
identiﬁcation of genetic modiﬁers is vital to minimize the
confounding effects of inter-patient variability in these trials.
Here we present evidence that a common null polymorphism in
the ACTN3 gene has a signiﬁcant effect on muscle strength and
function in young ambulant DMD patients. The ACTN3 577X
allele was associated with signiﬁcantly reduced muscle strength
and poorer performance in the 10m walk test. Interestingly, the
ACTN3 577XX genotype is also associated with reduced 40m
sprint times in healthy adolescent males15, which mirrors our
ﬁndings in DMD patients. Muscles from dKO mice also produce
signiﬁcantly less force than their mdx counterparts, but show
increased recovery from fatigue. Taken together, these data
strongly suggest that a-actinin-3 deﬁciency results in reduced
power output in dystrophic muscle and that ACTN3 R577X
genotype should be considered when evaluating quantitative
muscle tests in DMD patients.
Susceptibility to stretch-induced damage is a well characterized
phenotype in dystrophic muscle28,39,40, and it worsens as the
disease progresses30. The young (8-week old) dKO mice show a
greater percentage of EBD containing muscle ﬁbres following a
single downhill run. However, there was no difference in
susceptibility to eccentric contraction damage when measuring
isolated ex vivo EDL of young dKO compared with mdx control
mice. This is an important comparison. In isolation the downhill
run analysis would suggest that the absence of a-actinin-3 results
in a larger number of damaged muscle ﬁbres; however ex vivo
analysis of EDL muscles suggest that there is no effect of genotype
in muscle damage properties at 8 weeks of age. In this case, the
in vivo approach of downhill running is likely confounded by the
observation that Actn3 KO mice are able to run further and more
effectively than WT mice20. The isolated EDL analysis removes
the intrinsic aspect of Actn3 genotype-associated running
performance from this analysis and allows us to observe the
primary effect of a-actinin-3 deﬁciency. Taking both data into
account, it is reasonable to assess that dKO muscle shows a
similar susceptibility to stretch-induced damage compared with
mdx at 8 weeks.
At 12 months old however, a-actinin-3 deﬁciency exhibits a
signiﬁcant protective effect against stretch-induced damage,
with dKO mice showing a B34% reduction in force deﬁcit
following eccentric contraction. Given that we saw no difference
between dKO and mdx at 8 weeks, and that susceptibility to
stretch-induced damage is known to increase with age, this
suggests that a-actinin-3 deﬁciency alters the mdx pathology
over time. Because this is an important ﬁnding, we re-tested the
phenotype in the TA using an in situ muscle function
assessment which some consider to be the gold-standard for
examining functional differences in muscle performance in
rodents. Again we saw a signiﬁcant amelioration in the
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Figure 3 | Muscle pathology from aged mdx and dKO mice. (a) Hemato-
xylin and eosin (H&E) stained TA sections from WT, mdx and dKO mice.
Scale bar indicates 100mm. (b) dKO muscles showed a signiﬁcant reduction
in total necrotic area compared with mdx (mdx – 10.7% versus dKO –
4.7%). (c) Both mdx and dKO show an increase in centrally nucleated ﬁbres
compared with WT, and dKO show a further increase compared with mdx
(dKO – 79% versus mdx 71%, Po0.05). Data shown as mean±s.e.m.,
One-way ANOVA, *Po0.05, **Po0.01, ***Po0.001. WT n¼ 11, mdx
n¼ 12, dKO n¼ 11. (d) Individual ﬁbres were isolated from 12 month old
EDLs to assess ﬁbre branching. The left hand panel shows an entire intact
ﬁbre from mdx with a branch which originates from the main body of the
ﬁbre which re-joins at the mid-belly of the ﬁbre (indicated by arrows). The
right hand panels show higher magniﬁcation examples of ﬁbre branching.
Scale bar indicates 100 mm. (e) Almost all ﬁbres isolated from mdx (99%)
and dKO (89%) are branched. (f) However, mdx show a higher number of
branches per ﬁbre than dKO; 74% of mdx ﬁbres have 4 or more branches
compared with 18% of dKO. Fibre counts are pooled (n¼ 3 mice per
genotype) with B600 ﬁbres analysed per genotype.
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susceptibility to stretch-induced damage in dKO muscle
compared with mdx, conﬁrming our ﬁndings from the EDL.
Finally we looked at ﬁbre branching morphology, as branched
ﬁbres are also known to accumulate with disease progression
in dystrophic muscle41 and correlates with susceptibility to
stretch-induced damage42. The observed reduction in branching
complexity in dKO mouse muscle at 12 months directly
correlates with the decreased susceptibility to eccentric
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Figure 4 | Longitudinal analysis of the CINRG cohort. (a) Kaplan-Meier survival analysis for age at loss of ambulation (LoA) in 266 CINRG Duchenne
Natural history Study participants. Heterozygous (RX) participants suffered 1- to 2-year earlier LoA with a median age of 11.7 years (95% CI 11.0–13.0), as
opposed to 12.5 (11.1–14.0) in RR and 13.0 (11.9–14.0) in XX. (b) Longitudinal analysis of grip QMT in steroid-treated 6 to 10 year old DMD patients. They
are not necessarily the same subjects throughout the 48 month period of testing. Some subjects only met the criteria in the middle of the study and others
were only included in the analysis for a few time points. Error bars represent mean±95% CI.
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Figure 5 | Fibre size is reduced in dKO mice. (a) Representative image of ﬁbre typing in WT quadriceps. Sections cut from the midbelly of 12 month old
male quadriceps were stained with antibodies against MyHC Type 1 (green), 2A (blue) and 2B (red), while 2X ﬁbres were left unstained. A488 conjugated
wheat germ agglutinin was used to mark membranes to delineate the individual ﬁbres (Green). Scale bar indicates 500mm. (b) Fibre size frequency
distribution for all quadriceps ﬁbres (Approx 7,000 per quadriceps). The mean ﬁbre size was reduced in dKO compared with mdx (1781±158 mm2 versus
1223±242mm2, Po0.05). (c) Frequency distribution for all 2B ﬁbres in the quadriceps. Mean 2B ﬁbre size is reduced in dKO compared with WT
(1950±213mm2 versus 1670±267mm2, Po0.05). (d) Individual ﬁbre types presented as a percentage of total ﬁbre number show no shift in ﬁbre type
proportion across all the genotype groups. Data shown as mean±s.e.m., WT n¼ 6, mdx n¼ 7, dKO n¼6.
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damage. In combination, these data provide strong evidence to
suggest that dystrophic progression is slowed in a-actinin-3
deﬁcient muscle.
While we show evidence that a-actinin-3 deﬁciency amelio-
rates disease progression in mdx mice, examining an effect
of ACTN3 on progression in DMD patients is much more
challenging. ACTN3 genotype has a signiﬁcant effect on LoA in
the CINRG cohort, but this is largely driven by a reduced
ambulation in heterozygous (RX) patients compared with both
homozygous groups. Biologically, this is difﬁcult to explain,
but we have recently shown evidence for haploinsufﬁciency
associated with ACTN3 (ref. 43), which may explain this
phenomenon. Preliminary analysis shows that Actn3þ / mdx
muscles display reduced force (comparable to dKO), but not
the protection against stretch-induced damage seen in dKO
muscle (Supplementary Fig. 5). Although further investigation is
required, it appears that loss of a single ACTN3 allele does not
drive muscle adaptation enough to ameliorate the progression of
the dystrophic phenotype in mdx mice and hence heterozygous
mice presumably suffer the disadvantage associated with reduced
a-actinin-3 expression (that is, reduced strength), but do not gain
any of the associated advantageous phenotypes (protection of
muscle damage).
In human populations, ACTN3 association studies may also be
confounded by population stratiﬁcation, as the null allele is more
frequent in non-European populations (1000 Genomes), who
might also present a different DMD phenotype severity because
of standard of care disparity or different genetic background. Age
at LoA in the heterozygous genotype was earlier in both the
CINRG European ancestry sub-cohort, and the Padova cohort
(also of European ancestry). In the latter, the XX genotype
behaved more similarly to RX (early LoA) rather than to RR as in
the CINRG cohort, but the number of XX individuals was low
(n¼ 10), making this estimate scarcely accurate. In the merged
European populations (n¼ 297), the association of earlier LoA
Actinin-3
3
2 *
*
R
el
at
iv
e 
O
D
1
R
el
at
iv
e 
O
D 1.5
0.5
0.0
ACC p-ACC AMPK p-AMPK
2.0
1.0
0
Actinin-2 Utrophin RCAN 1.4
mdx mdxdKO dKO
Actinin-2
Utrophin
RCAN 1.4
Actin
* * *
*
R
el
at
iv
e 
O
D 1.5
0.5
0.0
2.0
1.0
ATPase COX III COX II COX I COX IV
a b
mdx dKO
ATP synthase
Complex III
Complex II
Complex I
Complex IV
Actin
e
ACC
p-ACC
AMPK
p-AMPK
Actin
0.5× 2× 1× mdx dKOc d
f
Figure 6 | Relative protein expression in dKO muscle compared to mdx. (a,b) dKO muscle at 12-months of age show a compensatory upregulation of
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presented in Supplementary Fig. 6.
Table 3 | Physiological properties of isolated EDLs from aged
WT, mdx and dKO mice.
Parameter WT mdx dKO
EC50 (Hz) 50.2±0.7 60.9±0.3* 57.0±1.6*
Hill co-efﬁcient 3.8±0.2 4.3±0.2 4.1±0.3
Twitch time to peak (ms) 24.6±0.6 18.0±0.7* 18.9±2.5*
Twitch half-relax time (ms) 17.2±2.4 10.2±0.8* 18.2±6.6w
One-way ANOVA.
*Po0.01 versus WT.
wPo0.01 versus mdx.
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with the heterozygous genotype proved signiﬁcant independent of
the effects of other known genetic modiﬁers and corticosteroid
treatment. When the LoA analysis was restricted to European
ethnicity, XX individuals showed prolonged ambulation of 1 year
on average compared with RR, but this difference was not
signiﬁcant. The observation of a detrimental effect of the
heterozygous, but not of the null homozygous genotype, was
unexpected. LoA is a more complex phenotype than sheer muscle
strength, as ambulatory function involves compensatory mechan-
isms, relative involvement of different muscle groups, and joint
contractures. Thus, it could be that the metabolic and ﬁbre type
changes induced by ACTN3 deﬁciency at various levels affect the
balance between these variables in a complex manner. Further
genotyping of larger cohorts is warranted to strengthen this
conclusion.
We made a similar observation when analysing grip strength
over time, as ACTN3 genotype had a signiﬁcant effect, but we
lacked the statistical power to compare individual genotypes.
However, scrutinizing the results presented in Fig. 4b suggests
that XX individuals show a favourable gradient relative to RR,
indicating the a-actinin-3 deﬁciency may protect against the loss
of strength over time. It is clear from both the LoA and
longitudinal grip strength analyses that any effect of ACTN3 on
the progression of DMD is subtle and hence large scale cohort
analysis will be required to determine the effect with any
certainty. However, we do present strong evidence indicating that
ACTN3 genotype modiﬁes muscle strength in DMD and
therefore should be included as a covariate in the analysis of
functional outcomes for all future clinical trials.
Slow ﬁbres are relatively spared from degeneration in both
DMD biopsies24 and mdx mice28; understanding the basis of this
‘protective effect’ of slow ﬁbres could provide important insights
into potential therapies for DMD. Promoting fast-to-slow ﬁbre
type conversion by calcineurin overexpression25,26 or chronic
pharmacological activation of AMPK (refs 34,35) in mdx mice
ameliorates the dystrophic pathology and protects against stretch-
induced damage. Both interventions result in a decrease in ﬁbre
size, increased utrophin expression and a shift towards oxidative
metabolism; each of these characteristic properties of slow ﬁbres
may modify the dystrophic phenotype. dKO muscles show a
reduction in overall ﬁbre size, which is a product of smaller 2B
ﬁbres as these are the major constituent of the quadriceps and the
only ﬁbre type which expresses a-actinin-3 (ref. 44). However, we
did not see a change in the expression of utrophin, but this is
consistent with the lack of fast-to-slow ﬁbre type conversion in
dKO muscle. Interestingly, dKO muscle displays a physiological
increase in calcineurin (RCAN1.4) and AMPK signalling, which
result in a similar phenotype to the aforementioned models,
including; reduced force production, increased recovery from
fatigue and protection against stretch-induced damage. In line
with these studies, we see a shift in the contractile properties of
dKO muscle towards a slower twitch phenotype, which is
accompanied by increases in markers of oxidative metabolism
as demonstrated by increased Pgc1-a mRNA expression
(Supplementary Fig. 4) and upregulated ATP synthase, complex
II, III and IV protein expression.
We have previously demonstrated that a-actinin-3 deﬁciency
results in a shift toward a slow-twitch, oxidative metabolic
phenotype18,21, which is known to be impaired in mdx
muscle45,46 and contributes to pathology by compromising
skeletal muscle integrity47. Hence, it is likely that the shift
towards oxidative metabolism associated with a-actinin-3
deﬁciency underlies the protective effect observed in dKO mice.
Previous studies have shown that manipulation of either calci-
neurin25,31 or AMPK signalling35,36 ameliorates the pathology of
mdx mice. But, in both cases, the approaches used increased
activity several fold above wild type levels; here we show that
physiological alterations in these pathways by a single genetic
variant is enough to have a signiﬁcant effect. This has important
implications for the management of DMD patients moving
forward; many current treatment strategies including mysotatin
inhibition aim to ameliorate progression by inducing muscle
hypertrophy to counteract muscle weakness48, but our results
from a-actinin-3 deﬁcient muscle suggest that pharmacological
and exercise interventions which promote a shift towards slow,
oxidative metabolism and reduced ﬁbre size may be more
beneﬁcial in the long term.
Metabolic dysfunction is a common feature across many
different genetic muscle diseases7,49 and the age-related decline in
muscle function50,51. Hence, we believe that the genetic modiﬁer
effect of ACTN3 is not limited to DMD, but is likely to be more
broadly applicable to a wide cross-section of muscle pathologies.
Methods
Statistical analysis of the CINRG and Padova human cohorts. We received
approval from ethical standards committees on human experimentation
(institutional or regional) for any experiments using human subjects, and written
informed consent was obtained from all patients (or guardians of patients)
participating in the study (consent for research), as previously reported for the
CINRG (refs 5,52) and Padova5 cohorts. Velocity and QMT values from the
CINRG natural history cohort were tested for normality using the Shapiro–Wilk
normality test and visual inspection of histograms. All QMT values were found to
be skewed; therefore all analyses were performed on square root transformed QMT
values. Mean values were compared among ACTN3 genotypes via one-way analysis
of variance with post-hoc pair-wise comparisons done and adjustment of P-values
for multiple comparisons using the Sˇida´k method. P valuesr0.05 were considered
statistically signiﬁcant. Muscle biopsies from this cohort were not available for
further molecular analysis.
Further analysis of velocity and QMT values over time were performed using
mixed effect linear regression models. The models were ﬁt with velocity or QMT as
the dependent variable, genotype and time as ﬁxed effects and subject with a
random intercept and slope.
Loss of independent ambulation (LoA) in the CINRG Duchenne Natural
History Study (DNHS) was deﬁned as continuous wheelchair use, conﬁrmed by
inability to walk 10m unassisted. Genotyping was performed by a TaqMan
genotyping assay. The effect of ACTN3 genotype on LoA was studied in a time-
to-event statistical framework, with age as a time variable and LoA as event, and
censoring participants who were still ambulatory at last follow-up. Genotype effect
on LoA was tested by Cox regression, with glucocorticoid (GC) treatment as a
covariate (treatment for at least 1 year while ambulatory versus untreated or treated
o1 year), and modelling genotype as a 3-way categorical variable (RR, RX or XX),
as an additive effect (number of copies of the X allele), or as a dominant effect
(no copies versus at least 1 copy of the X allele). This statistical analysis was run in
R version 3.2.1 (‘survival’ package). Minor allele frequency for rs1815739 varies
between ethnicities, and as there are differences in phenotype between different
races and ethnicities in the CINRG-DNHS cohort, this could lead to a population
stratiﬁcation bias. Therefore, analyses were run both in the whole (multi-ethnic)
CINRG-DNHS cohort (n¼ 266), and in a sub-cohort of European and European
American ancestry, controlled for population stratiﬁcation by multidimensional
scaling analysis (n¼ 114)52. We also aimed to replicate the results from the
CINRG-DNHS in a second cohort of DMD patients. To investigate this, the same
methodological approach described above was used to analyse the effect of ACTN3
genotype on LoA in the Padova cohort of DMD patients (n¼ 102).
Animals. Mdx (C57BL/10ScSn-Dmdmdx/J) mice were obtained from Jackson
Laboratories (Bar Harbor, ME, USA). The Actn3 knockout (KO) line created in this
laboratory21 was backcrossed onto the C57BL/10 background for 10 generations
before being crossed with the mdx line to produce mice lacking both a-actinin-3
and dystrophin (dKO). All animal experiments were approved by the Childrens
Medical Research Institute (CMRI) and Murdoch Childrens Research Institute
(MCRI) animal ethics committees and performed according to their prescribed
guidelines. Experiments were performed on male animals at 2 timepoints; 8±1
weeks (baseline) and 12±1 months (aged).
Muscle physiology assessment. Downhill run was performed in order to induce
muscle damage in vivo using a modiﬁed protocol53. Brieﬂy mice were forced to run
downhill in the presence of Evans blue dye (EBD) injected intraperitoneally 30min
before performing the downhill run protocol. Following EBD injection mice were
placed on an Accupacer treadmill (Columbus Instruments) set at a 15 decline and
run for 10min at a speed of 15m per min. Mice were euthanized 24 h after the
downhill run, and all hindlimb muscles were harvested. To visualize muscle
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damage, 8 mm sections were cut from the midpoint of the gastrocnemius muscle.
These were ﬁxed with 4% paraformaldehyde at 27 for 10min and then incubated
with Alexa488-conjugated wheat germ agglutinin (W11261, Life Technologies,
1:200) for 1 h to mark the boundaries between ﬁbres. EBD inclusion was imaged
using ﬂuorescent microscopy, at 620 nm (excitation) and 680 nm (emission). All
Fibres were then counted to determine the % of dye inclusion per cross section.
Ex vivo Extensor digitorum lognus (EDL) muscle physiology was performed
using WT, mdx and dKO mice. The EDL was carefully dissected from the lower
hindlimb and tied by its tendons to a force transducer (Fort series, World Precision
Instruments) at one end, and a linear tissue puller (University of New South Wales)
at the other using silk suture (Deknatel 6.0). The isolated muscle was placed in a
bath continuously perfused with Krebs solution, composed of (in mM) 4.75 KCl,
118 NaCl, 1.18 KH2PO4, 1.18 MgSO4, 24.8 NaHCO3, 2.5 CaCl2 and 10 glucose with
0.1% fetal calf serum and was continuously bubbled with carbogen (95%O2,
5%CO2) to maintain pH at 7.4.
The muscle was stimulated by delivering a supramaximal current between two
parallel electrodes in the bath using an electrical pulse generator (A-M Systems).
The optimal length (LO) was determined as the muscle length at which maximum
twitch force was generated prior to experimentation and set as the baseline.
A force frequency curve was obtained by delivering 500ms stimuli of different
frequencies (2, 15, 25, 25, 37.5, 50, 75, 100, 125 and 150Hz) and measuring the
force produced during each stimulation. A 30 sec rest was allowed between each to
mitigate the effects of fatigue. A curve relating to the muscle force and stimulation
frequency was ﬁtted to the data. From the ﬁtted curve the following parameters
were obtained; maximum force (Pmax), Hill coefﬁcient and twitch to tetanus ratio.
Following generation of the force frequency curve, the muscle was subjected
to a series of eccentric stretch contractions. Two distinct protocols were performed
to ensure adequate muscle damage was achieved at each time point. We have
previously shown that a 15% stretch in young (6-8 week old) mdx mice is
insufﬁcient to induce muscle damage30. Therefore at 8 weeks of age, muscles were
stimulated for 4 sec at 100Hz, and at t¼ 250ms when the maximum isometric
force was reached, and stretched to 20% longer than LO at a constant speed of
5mm per sec. The muscle was held at this extended length for 2 sec before being
returned to LO at 5mm per sec. This process was repeated six times, with a 3min
interval between each eccentric contraction. Following the ﬁnal stretch, the muscle
was allowed to recover for 10min before a second force frequency curve was
generated. The Pmax following the eccentric contractions was obtained from this
and subtracted from the original Pmax to give the raw force deﬁcit. Finally, the raw
force deﬁcit was expressed as a percentage of the pre-stretch Pmax for analysis. This
protocol was altered for muscles from aged mdx mice because of the more
advanced disease; muscles were stimulated for 5 sec at 100Hz, and stretched to 15%
longer than LO at a constant speed of 2mm per sec. The muscle was held at this
extended length for 2 sec before being returned to LO at 2mm per sec. This process
was repeated three times at 5min intervals and the muscle was allowed to recover
for 10min before the force deﬁcit was calculated.
A separate set of muscles were used to analyse the recovery from fatigue.
Following generation of a force frequency curve and after a 10min rest, muscles
were subjected to the following fatigue protocol; repeated 1 sec tetani at 100Hz
every 2 sec for a period of 30 sec. To track the recovery, the force produced by short
(250ms) 100Hz tetani was recorded at 30 sec, 1, 2, 3, 5 and 10min post fatigue.
The force produced during each of the 100Hz tetani during the fatigue protocol
and subsequent recovery was recorded and expressed relative to the pre-fatigue
force.
In situ assessment of the tibialis anterior (TA) was performed in aged
(12 month old) WT, mdx and dKO mice (n¼ 5–7 mice per genotype) using the
Arora Scientiﬁc 1300A whole mouse test system and 701C stimulator. Brieﬂy, mice
were anaesthetized using isoﬂurane inhalation (0.6ml per min) and placed on a
37oC heated platform, the distal tendon of the TA was surgically isolated and the
knee joint exposed. Surgical silk (Silicon coated suture silk 5/0, Covidien) was used
to secure the TA tendon to the force transducer (Model 809B in situ test
apparatus), the foot and knee were clamped in place for stability. Maximum tetanic
force (mN), speciﬁc force (mN per mm2) and the degree of contraction-induced
damage (% force loss) were determined, as previously outlined in Percival et al.54
with minor modiﬁcations. Brieﬂy, the TA muscle was adjusted to an optimum
length (Lo) to produce maximum twitch force (Pt), and the ﬁbre length (Lf)
was calculated using the correction value of 0.6 (Lf¼ Lo 0.6). The TA was
then stimulated every 2min at increasing frequencies (5–250Hz) to generate
force–frequency curves. Maximal tetanic force (Po) was typically achieved at
150Hz. Both Lo and TA mass were recorded and used to determine Pt, Po
and speciﬁc tetanic (sPo) force for each muscle.
The TA muscle from each subject underwent a series of lengthening
contractions of progressively increased strain (0–35%). Strain is the percentage
increase in length beyond the optimal Lf. Muscles were maximally stimulated
(7mA, at 150Hz) for 150ms at Lo to achieve maximal isometric tension,
immediately followed by 200ms of stimulation during the application of a 5%
increase in length (ranging from 0 to 35%) beyond Lf. Stretch was applied at a rate
of 2 ﬁbre lengths per sec with 30 sec intervals between each stretch. The force (Po)
generated immediately prior to the initiation of the subsequent lengthening
contraction was recorded and normalized to the starting force to calculate % force
generated.
Tissue collection. Mice were euthanized via cervical dislocation. The skin was
removed from the hindlimb and individual muscles were dissected out, with
overlying fascia and adipose tissue discarded. The wet weight of the isolated
muscles was recorded immediately upon excision to minimize the effect of
evaporation on the measurement. Following this, the individual muscles were
covered in a cryo-preservation medium (TissueTek) and frozen in liquid
nitrogen-cooled isopentane. Tissue was stored at  80 until use.
Muscle histopathohlogy and ﬁbre morphology. Histological assessments were
performed in the TA of 12 month old mdx and dKO mice (n¼ 10–14 mice per
genotype). Brieﬂy, the TA of WT, mdx and dKO mice were removed and weighed
before being frozen in liquid nitrogen cooled isopentane, samples were stored at
 80 C until use. The TA were cut through the mid-belly and 8 mm sections
were collected and placed on Superfrost-Plus microscope slides (Thermo ﬁsher
Scientiﬁc). Hematoxylin and eosin (H&E) staining was performed as outlined
previously55. Muscles were frozen in liquid nitrogen pre-chilled isopentane and
stored at  80 C until analysis. Muscles were cryo-sectioned at 8 mm and placed
on a microscope slide. The sections were incubated in Haematoxylin (for 5min,
HHS32, Sigma Aldrich) and Eosin (for 2min; HT110232, Sigma Aldrich) and
the whole TA cross-section was imaged using a scanning light microscope
(Leica Biosystems). Images were imported into ImageJ for analysis56. All
histological analyses were performed according to the Treat-NMD preclinical
standard operating procedures (SOPs) while blinded to genotype.
Fibre branching morphology was performed using individual ﬁbres isolated
from the EDL of WT, mdx and dKO mice (n¼ 3 mice per genotype). The muscles
were digested in Krebs solution (in mM): 1.2 NaH2Po4, 1 MgSO4, 4.83 KCl, 137
NaCl, 24 NaHCO3, 2 CaCl2, 10 Glucose, with 3mg per ml collagenase IV (C5138,
Sigma-Aldrich), which was bubbled with carbogen and incubated at 37 C. After
30min, the muscles were removed from the digesting solution, rinsed in Krebs and
placed in a relaxing solution (in mM): 117 Kþ , 36 Naþ , 1Mg2þ , 60 HEPES, 8
ATP, 50 EGTA2 , with free Ca2þ of 10 7 M. Individual ﬁbres were obtained by
gently agitating the muscle with a pipette and their morphology was examined
under a light microscope. Fibre morphological analyses were performed blinded
to genotype and digital-photographic representations recorded for all ﬁbres
(mdx, n¼ 272 ﬁbres and dKO, n¼ 608 ﬁbres).
Myosin heavy chain proﬁle. Transverse 8 mm sections were cut from the
midpoint of the quadriceps muscle. These sections were blocked with 2% BSA for
10min before being incubated overnight at 4 C with an antibody against myosin
heavy chain 2B (BF-F3, DSHB, University of Iowa, USA, 1:10 dilution) and
Alexa488-conjugated wheat germ agglutinin (W11261, Life Technologies, 1:500).
Following primary incubation sections were washed three times with PBS and
re-blocked with 2% BSA for 10min. Secondary antibodies, Alexa555 goat anti-
mouse IgM (A-21426, Molecular Probes, 1:500) and Alexa 488 goat anti-rabbit IgG
(A-11008, Molecular Probes, 1:500) were then applied for 2 h at room temperature.
Sections were washed three times in PBS and blocked with AfﬁniPure fab fragment
goat anti-mouse IgG (115-007-003, Jackson ImmunoResearch, 1:200) for 1 h.
Immediately following this, sections were incubated with antibodies against slow
myosin type 1 (MAB1628; Chemicon, 1:100) and myosin heavy chain 2A (SC71;
DSHB, University of Iowa, used neat), covalently labelled with Alexa 488 and Alexa
350 respectively, with a Zenon labelling kit (Z25070, Invitrogen) for 2 h at room
Table 4 | RT-qPCR primers and conditions.
Gene ID Accession number Forward oligo sequence (50–30) Reverse oligo sequence (50–30) Product size (bp) Temp (C) Intron spanning
Actb NM_007393 CCTCCCTGGAGAAGAGCTATG TTACGGATGTCAACGTCACAC 157 65 Yes
Rn18s NR_003278 GCAATTATTCCCCATGAACG GGCCTCACTAAACCATCCAA 124 65 N/A
Rer1 NM_026395 GCCTTGGGAATTTACCACCT CTTCGAATGAAGGGACGAAA 137 62 Yes
Rpl41 NM_018860 GCCATGAGAGCGAAGTGG CTCCTGCAGGCGTCGTAG 113 65 Yes
Pgc1a NM_008904 CAACAATGAGCCTGCGAAC AGGGCAATCCGTCTTCATC 116 65 Yes
Forward and reverse oligonucleotide sequences (50–30), product size and annealing temperature for each reference gene (Rer1, Rpl41, Rn18S, Actb) and Pgc1a.
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temperature. Finally sections were washed three times in PBS to remove any
unbound antibody, ﬁxed with 4% paraformaldehyde for 10min and coverslips were
mounted. These whole IHC-stained sections were imaged at  40 using ProgRes
camera and software (SciTech). The ﬁbre diameter and number was analysed using
MetaMorph software according to published protocols57.
Protein expression analysis. The snap frozen quadriceps from each mouse were
ground using a liquid nitrogen-cooled mortar and pestle. Approximately 2mg of
the ground tissue was solubilized in 500ml 4% SDS buffer containing 50mM Tris,
10% glycerol, 50mM DTT, bromophenol blue and protease inhibitor cocktail
(Sigma-Aldrich). The concentration of total protein in each sample was assessed
using a BCA protein assay kit (Thermo Fisher).
Up to 50 mg of protein lysate was loaded onto 4–12% Bis–Tris precast minigels
(Life Technologies), separated by SDS–PAGE and transferred onto polyvinylidene
ﬂuoride membranes (Millipore). The membranes were incubated with antibodies
against a-actinin-2 and -3 (gift from Alan Beggs, Children’s Hospital Boston),
AMPKa (Total (5,831) and Thr172 (2,535) Cell Signalling, 1:1,000), Acetyl-CoA
Carboxylase (ACC total (3,676) and Ser79 (11,818) Cell Signalling, 1:1,000),
utrophin (DRP2-CE-S, Novocastra, 1:1,000), RCAN 1.4 (D6694; Sigma-Aldrich,
1:500), MitoProﬁle Total OXPHOS antibody cocktail (AB110413, Abcam, 1:2,000),
COX IV (20E8; Molecular Probes, 1:1,000) and Pgc1a (AB3242, Merk Millipore,
1:1,000). a-Sarcomeric actin (A2172, 5C5, Sigma-Aldrich, 1:2,000), was used as a
loading control, and after developing, membranes were stained with Coomassie
Brilliant Blue (1610436, Sigma-Aldrich), and the expression of myosin was used as
an additional loading control. Films were scanned using an Epson scanner, and the
optical density of bands was computed using ImageJ software (NIH).
Quantitative real-time PCR (RT-qPCR). Total RNA was isolated from B50mg
of mouse quadriceps tissue using TRIzol (Invitrogen) according to the manu-
facturer’s instructions. The RNA was resuspended into 50 ml DEPC treated
water and puriﬁed and DNAseI treated using RNeasy Mini on-column clean-up
(Qiagen). RNA quality and quantity was assessed using a 2100 Bioanalyser (Agilent
Technologies) 6,000 RNA kit (Agilent Technologies) according to the manu-
facturer’s instructions. One microgram (1mg) of total RNA was reverse transcribed
using Super-Script III Reverse Transcriptase (Invitrogen), random pdN6 primers
(Roche), 0.1mM DTT (Invitrogen) and 10mM dNTP (Invitrogen) in a 20 ml
volume for 90min at 50 C on a Veriti 96-well thermocycler (Applied Biosystems).
All cDNA was diluted in DEPC treated water (Bioline) prior to RT-qPCR. Diluted
cDNA was aliquoted into working volumes of 10 ml and stored at  80 C until use.
Reverse transcriptase quantitative PCR (RT-qPCR) was performed using
standard curves generated from serially diluted plasmid constructs of each gene of
interest as outlined in Thomas et al.58 Relative gene expression was determined
using the geometric mean of four reference genes (Rer1, Rpl41, Rn18S, Actb) to
normalize Pgc1a mRNA expression in mdx and dKO (Table 4). Absolute Pgc1a
expression levels were determined based on the known DNA concentrations from
the Pgc1a standard curve using our previously published method58. RT-qPCR was
carried out using a Rotor-Gene 6000 (Qiagen) in a 20 ml reaction volume consisting
of, 1 ml mouse cDNA, 10 mM of forward and reverse primers,  1 MyTaq buffer
(Bioline), 0.2 U MyTaq DNA polymerase (Bioline), 0.4 ml  10 SYBR Green I
(Life Technologies) and DNAse-free water. All samples and plasmid DNA were
ampliﬁed in triplicate and a no-template-control (NTC) was included in each
reaction. Ampliﬁcation were performed with a 2min denaturation step at 95 C,
followed by 35 cycles of 95 C for 30 sec, 62–65 C (Table 4) for 30 sec and 72 C for
30 sec. Melt curve analysis was performed from 60–99 C to assess ampliﬁcation
speciﬁcity.
Statistical analysis of animal data. The methods used for analysis of animal data
are the same as those described for the analysis of velocity and QMT phenotypes in
the human data, namely analysis of variance methods with post-hoc pair-wise
comparisons where appropriate. This analysis was performed using GraphPad
Prism software.
Data availability. All relevant data are available from the authors. The human
cohort dataset is not publicly available, but can be obtained via formal request to
the CINRG consortium (www.cinrgresearch.org).
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